Brigatinib: up next in our pipeline

An FDA breakthrough therapy under investigation in ALK+ NSCLC

LEARN MORE

A remarkable place doing remarkable work

We're looking for people who want to make a difference for cancer patients

OPEN POSITIONS

A unique, highly targeted approach to cancer

Our research & development program

LEARN MORE

NEWS & FEATURES

Latest News

12/2/16
ARIAD to Host Webcast and Conference Call on Brigatinib Data Presentations at the World Conference on Lung Cancer
Read More
11/29/16
ARIAD Announces FDA Full Approval and Label Update for Iclusig® (ponatinib) Based on Long-Term Efficacy and Safety Data from Phase 2 PACE Clinical Trial
Read More

TWITTER FEED